Department of Respiratory Oncology, 117981Guangxi Cancer Hospital and Guangxi Medical University Affiliated Cancer Hospital, Nanning, Guangxi Zhuang Autonomous Region, China *Huiqin Jiang, Wei Jiang contributed equally to this work.
J Int Med Res. 2021 Apr;49(4):3000605211004229. doi: 10.1177/03000605211004229.
To investigate the prognostic value of pretreatment haemoglobin-to-red cell distribution width radio (HRR) in predicting overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC).
This retrospective study analysed patients with advanced NSCLC. Kaplan-Meier survival analysis and Cox proportional hazards regression analysis were conducted to evaluate the predictive value of HRR for OS. A propensity matching analysis was used to reduce the impact of other confounding factors on the results.
A total of 448 patients were enrolled in the study. The median HRR was 0.984, which was used as the cut-off value. Regardless of matching or not, a lower HRR was correlated with an unfavourable risk of death. After propensity matching, univariate and multivariate analysis showed that HRR was an independent factor for the prognosis of NSCLC (hazard ratio [HR] 1.55, 95% confidence interval [CI] 1.17, 2.04; HR 1.57, 95% CI, 1.17, 2.10; respectively). Kaplan-Meier analysis showed that low HRR was associated with shortened OS. The relationship between HRR and the risk of death was consistent across all patient subgroups after stratification by subgroup analysis.
These findings showed that a lower pretreatment HRR could be a potentially valuable prognostic factor in patients with advanced NSCLC.
探讨治疗前血红蛋白与红细胞分布宽度比（HRR）对晚期非小细胞肺癌（NSCLC）患者总生存期（OS）的预测价值。
本回顾性研究分析了晚期 NSCLC 患者。采用 Kaplan-Meier 生存分析和 Cox 比例风险回归分析评估 HRR 对 OS 的预测价值。采用倾向评分匹配分析以减少其他混杂因素对结果的影响。
共纳入 448 例患者。HRR 的中位数为 0.984，将其作为截断值。无论是否匹配，较低的 HRR 与死亡风险增加相关。在倾向评分匹配后，单因素和多因素分析表明 HRR 是 NSCLC 预后的独立因素（风险比[HR]1.55，95%置信区间[CI]1.17，2.04；HR 1.57，95%CI，1.17，2.10；分别）。Kaplan-Meier 分析表明，低 HRR 与 OS 缩短相关。分层亚组分析显示，HRR 与死亡风险之间的关系在所有患者亚组中均一致。
这些发现表明，治疗前较低的 HRR 可能是晚期 NSCLC 患者有价值的预后因素。
